Temozolomide 180 Pill — WHITE CAPSULE, 20mm — Temozolomide

No photo available
View full Temozolomide profile
ImprintTemozolomide / 180
ColourWHITE
ShapeCAPSULE
Size20
StrengthTemozolomide 180 mg;anhydrous lactose 316.3 mg;silicon dioxide 0.5 mg;sodium starch glycolate type A potato 27 mg;tartaric acid 5.4 mg;stearic acid 10.8 mg
Dosage formCapsule
ManufacturerSandoz Inc
NDC0781-2695
Schedule—
Availability—
IngredientsTemozolomide[Temozolomide];anhydrous lactose[];silicon dioxide[];sodium starch glycolate type A potato[];tartaric acid[];stearic acid[]

What does this imprint mean?

The imprint "Temozolomide 180" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Temozolomide

Uses and warnings

BOXED WARNING: Myelosuppression - "Myelosuppression, including pancytopenia, leukopenia...and anemia, some with fatal outcomes, have occurred," with approximately 10% of patients requiring hospitalization or transfusion; blood counts must be monitored, with nadirs typically around day 26-28. Hepatotoxicity - "Fatal and severe hepatotoxicity have been reported" and liver function should be checked at baseline, mid-cycle, and after each cycle. Secondary malignancies, including myelodysplastic syndrome and secondary leukemias, have been observed. Contraindicated in patients with prior serious hypersensitivity to temozolomide or dacarbazine (shared metabolite). Also warns of Pneumocystis pneumonia risk, especially with concurrent steroid use, and embryo-fetal toxicity.

Indicated for adults with "newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment," and for "adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma" as well as "treatment of adults with refractory anaplastic astrocytoma."

Read the full drug profile →

How to identify this pill

Similar-looking pills

Other pills of Temozolomide

Official references

Source: FDA Structured Product Label via NLM Pillbox archive (retired 2021); source file 54a86dfb-6436-4212-8744-dbfdc03a55f7.xml